This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

AVANIR Pharmaceuticals (AVNR)

NASDAQ: Health Care

Get a 5-page Ratings Report on (AVNR) now
$3.460.04 | 1.17%
04/17/14 - 4:00 PM ET
Company Profile
Price and Volume
Recent Price 3.42
52 Week High 6.00
52 Week Low 2.62
Avg. Daily Vol. (Mil) 2.28
Beta (3 year) 1.08
Share Related Items
Mkt Cap (Mil) 520.85
Shares Out (Mil) 152.30
Float (Mil) 130.47
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 1.60
Current Ratio 1.70
LT Debt/ Equity 2.08
Total Debt / Equity 3.29
Valuation Ratios
Price Earnings n.a.
Price/Sales 6.09
Price/Book 58.24
Price/Cash Flow -7.10
Per Share Data
Earnings -0.52
Sales 0.56
Book Value 0.06
Cash Flow -0.48
Business Summary
Avanir Pharmaceuticals is a biopharmaceutical company engaged in acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders.
General Information
20 Enterprise
Suite 200
Aliso Viejo, CA 92656
www.avanir.com
Industry : Drugs
Sector: Health Care
Employees: 267
CEO: Keith A. Katkin
Short Interest
Current Month (Mil) 15.84
Previous Month (Mil) 15.86
Short Interest Ratio (Days) 5.80
Management Effectiveness
Return on Equity n.a.
Return on Assets -121.30
Return on Investments -270.00
Profitability
Gross Margin 96.30
EBIT Margin -82.20
Profit Margin -86.90
(AVNR) News

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs